Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 326

The DOI matches its OpenAlex record.

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.

Open access
Francesco Diurno, Fabio Giuliano Numis, Giovanni Porta, Fernanda Cirillo, Sergio Maddaluno, Alfonso Ragozzino, Pasquale De Negri, C Di Gennaro, Antonio Pagano, Enrico Allegorico, L. Bressy, Giorgio Bosso, A Ferrara, Carlos Gala Serra, Andrea Montisci, Maria D’amico, S Schiano Lo Morello, G Di Costanzo, A.G. Tucci, P. Marchetti, U. Di Vincenzo, I Sorrentino, Antonio Casciotta, M Fusco, Carlo Buonerba, Massimiliano Berretta, Manuela Ceccarelli, Giuseppe Nunnari, Y. Diessa, Silvana Cicala, Gaetano Facchini·2020·PubMed

Abstract

OBJECTIVE: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related pneumonia, referred to as COVID-19 (Coronavirus Disease 19), is a public health emergency as it carries high morbidity, mortality, and has no approved specific pharmacological treatments. In this case series, we aimed to report preliminary data obtained with anti-complement C5 therapy with eculizumab in COVID-19 patients admitted to intensive care unit (ICU) of ASL Napoli 2 Nord. PATIENTS AND METHODS: This is a case series of patients with a confirmed diagnosis of SARS-CoV2 infection and severe pneumonia or ARDS who were treated with up to 4 infusions of eculizumab as an off-label agent. Patients were also treated with anticoagulant therapy with Enoxaparin 4000 IU/day via subcutaneous injection, antiviral therapy with Lopinavir 800 mg/day + Ritonavir 200 mg/day, hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamine C 6 g/day for 4 days, and were on Non-Invasive Ventilation (NIV). RESULTS: We treated four COVID-19 patients admitted to the intensive care unit because of severe pneumonia or ARDS. All patients successfully recovered after treatment with eculizumab. Eculizumab induced a drop in inflammatory markers. Mean C Reactive Protein levels dropped from 14.6 mg/dl to 3.5 mg/dl and the mean duration of the disease was 12.8 days. CONCLUSIONS: Eculizumab has the potential to be a key player in treatment of severe cases of COVID-19. Our results support eculizumab use as an off-label treatment of COVID-19, pending confirmation from the ongoing SOLID-C19 trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.26355/eurrev_202004_20875

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 326

Metadata

Authors
Diurno, F., Numis, F. G., Porta, G., Cirillo, F., Maddaluno, S., Ragozzino, A., Negri, P. D., Gennaro, C. D., Pagano, A., Allegorico, E., Bressy, L., Bosso, G., Ferrara, A., Serra, C. G., Montisci, A., D’amico, M., Morello, S. S. L., Costanzo, G. D., Tucci, A. G., Marchetti, P., Vincenzo, U. D., Sorrentino, I., Casciotta, A., Fusco, M., Buonerba, C., Berretta, M., Ceccarelli, M., Nunnari, G., Diessa, Y., Cicala, S., & Facchini, G.
Venue
PubMed
Publisher
National Institutes of Health
Published
2020-04-01
Volume
24
Issue
7
Pages
4040-4047
OpenAlex
W3018424597
Cited by
326
References
0
FWCI
9.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. https://app.cochat.ai/papers/10.26355/eurrev_202004_20875
The paper
Diurno, F., Numis, F. G., Porta, G., Cirillo, F., Maddaluno, S., Ragozzino, A., Negri, P. D., Gennaro, C. D., Pagano, A., Allegorico, E., Bressy, L., Bosso, G., Ferrara, A., Serra, C. G., Montisci, A., D’amico, M., Morello, S. S. L., Costanzo, G. D., Tucci, A. G., . . . Facchini, G. (2020). Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. PubMed. https://doi.org/10.26355/eurrev_202004_20875

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.